Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 0.96 |
| ▸ | ESR2 known ✓ | Q92731 | 19/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | TP53 | P04637 | 2/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | MAPT | P10636 | 2/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.96 |
| ▸ | PLD2 | O14939 | 1/20 | 0.96 |
| ▸ | KDM1A | O60341 | 1/20 | 0.96 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.96 |
| ▸ | USP2 | O75604 | 1/20 | 0.96 |
| ▸ | C5 | P01031 | 1/20 | 0.96 |
| ▸ | FYN | P06241 | 1/20 | 0.96 |
| ▸ | PGR | P06401 | 1/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821250 | 0.98 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL29362592 | 0.98 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL6144 | 0.98 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL3162158 | 0.98 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL9145135 | 0.98 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665344 | 0.97 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9201404 | 0.97 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL1665291 | 0.97 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL7630144 | 0.97 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL973873 | 0.97 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14641 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| US-12478683-B2 | Brush prodrugs and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-11-25 | — | — | US | claimed |
| EP-4638443-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | claimed |
| WO-2025217110-A1 | LIPID NANOPARTICLES FOR DRUG DELIVERY AND METHODS FOR MAKING AND USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250232860-A1 | SMART DOSING FOR CANCER THERAPY | OPTIMDOSING LLC (US) | 2025-07-17 | — | — | US | claimed |
| US-12300370-B2 | Smart dosing for cancer therapy | OptimDosing, LLC (US) | 2025-05-13 | — | — | US | claimed |
| WO-2025076010-A1 | SITE-SELECTIVE CONJUGATION OF A PHARMACEUTICAL AGENT TO AN ANTIBODY USING AN AFFINITY PEPTIDE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-04-10 | — | — | WO | claimed |
| US-5811120-A | COMBINED WITH SORBITAN FATTY ACID ESTER OR POLYOXYETHYLENE SORBITAN FATTY ACID ESTER SURFACTANTS, POLYVINYLPYRROLIDONE, AND WATER SOLUBLE DILUENT POLYOL OR SUGARS;USEFUL FOR OSTEOPROSIS IN POSTMENOPAUSAL WOMAN AND ANTITUMOR AGENT | ELI LILLY AND COMPANY (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998018325-A1 | PROPHYLAXIS OF BREAST CANCER | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | claimed |
| WO-1997035571-A1 | BENZOTHIOPHENES, FORMULATIONS CONTAINING SAME, AND METHODS | ELI LILLY AND COMPANY (US) | 1997-10-02 | — | — | WO | claimed |
| EP-0781555-A1 | Benzothiophene formulations of a specific dosage | ELI LILLY AND COMPANY (US) | 1997-07-02 | — | — | EP | claimed |
| EP-0584952-B1 | Improvements in or relating to benzothiophenes | LILLY CO ELI (US) | 1997-05-02 | — | — | EP | claimed |
| CN-1112420-A | Orally administerable pharmaceutical formulations | LILLY CO ELI (US) | 1995-11-29 | — | — | CN | claimed |
| EP-0670162-A1 | Pharmaceutical formulations containing raloxifere, a surfactant and a watersoluble diluent | ELI LILLY AND COMPANY (US) | 1995-09-06 | — | — | EP | claimed |
| EP-0605193-A1 | Use of benzothiophenes for treatment of hypercholesterolaemia | ELI LILLY AND COMPANY (US) | 1994-07-06 | — | — | EP | claimed |
| CN-1088205-A | The improvement of thionaphthene and correlative thereof | LILLY CO ELI (US) | 1994-06-22 | — | — | CN | claimed |
| EP-0584952-A1 | Improvements in or relating to benzothiophenes | ELI LILLY AND COMPANY (US) | 1994-03-02 | — | — | EP | claimed |